MAPK

Items 451-500 of 817

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. SOS1 Inhibitor

    KRAS G12C inhibitor 56 is a selective SOS1 inhibitor that exhibits potent inhibitory activity with an IC50 of 1.6 nM. This compound is relevant for cancer research, particularly in studies targeting KRAS-driven malignancies, and may provide insights into therapeutic strategies for tumors harboring KRAS G12C mutations. Researchers can leverage this inhibitor to explore the biochemical mechanisms of cell signaling and proliferation linked to KRAS activation.
  2. ONO 2506 inhibits S100B synthesis in activated cultured astrocytes.
  3. p38 MAPK inhibitor

    ML-3043 is a p38 MAPK inhibitor (IC50 = 0.38 μM). Inhibits the release of IL-1β and TNF-α in a peripheral blood mononuclear cell (PBMC) assay (IC50 values are 0.039 and 0.16 μM respectively).
  4. MLKL inhibitor

    TC13172 is a mixed lineage kinase domain-like protein (MLKL) inhibitor with an EC50 value of 2 nM for HT-29 cells.
  5. p38 MAPK inhibitor

    Losmapimod, also know as GW856553 or GW856553X, is a drug developed by GlaxoSmithKline which acts as a selective inhibitor of the enzyme family known as p38 mitogen-activated protein kinases.
  6. RAF inhibitor

    PF-04880594 is an inhibitor of RAF with IC50 values of 0.19 nM/0.13 nM and 0.39 nM for BRAF/BRAFV599E and c-RAF, respectively.
  7. p38 MAPK inhibitor

    Talmapimod (SCIO-469) is a selective, ATP-competitive p38 inhibitor (IC50 = 9 nM for p38α in vitro).
  8. food flavouring

    2',5'-Dihydroxyacetophenone (DHAP, 2-Acetylhydroquinone, Quinacetophenone) is a mixture of dihydroxyacetophenone isomers is used in food flavouring. 2',5'-Dihydroxyacetophenone significantly inhibits NO production via the suppression of iNOS expression. 2',5'-Dihydroxyacetophenone significantly decreases levels of the pro-inflammatory cytokines TNF-α and IL-6 by blocking the ERK1/2 and NF-κB signaling pathways.
  9. RAS/RAF/MAPK inhibitor

    Diazepinomicin, also known as TLN-4601, is a small-molecule inhibitor of the RAS/RAF/MAPK signaling pathway with potential antineoplastic activity.
  10. MEK1 inhibitor

    GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with Ki of 0.13 nM. Phase 1.
  11. Ras/Raf/MEK inhibitor

    Balamapimod, also known as MKI-822, is a Ras/Raf/MEK inhibitor.
  12. SOS1 inhibitor

    SOS1-IN-1 is a SOS1 inhibitor.
  13. MEK inhibitor

    EBI-1051 is a highly potent and orally efficacious MEK inhibitor with an IC50 of 3.9 nM.
  14. pan RAF inhibitor

    Belvarafenib (HM95573) is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively.
  15. MEK1 inhibitor

    RO4987655 is an orally active small molecule, targeting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity.
  16. Raf inhibitor

    ML 786 dihydrochloride is a potent Raf kinase inhibitor (IC50 values are 2.1, 2.5 and 4.2 nM for B-RafV600E, C-Raf and wild-type B-Raf respectively).
  17. pan-Raf inhibitor

    MLN 2480 is an oral, selective pan-Raf kinase inhibitor in chinical trials.
  18. MEK1/2 inhibitor

    RO4927350 a potent and highly selective non-ATP-competitive MEK1/2 inhibitor.
  19. MEK inhibitor

    Refametinib is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.
  20. JNK inhibitor

    AEG 3482 is a small-molecule inhibitor of Jun kinase (JNK)-dependent apoptosis.
  21. MK2 Inhibitor

    PF-3644022 is a potent and selective mitogen-activated protein kinase (MAPK)-activated protein kinase-2 (MK2) inhibitor (Ki =3 nM).
  22. BRAF inhibitor

    BRAF inhibitor is a potent BRAF inhibitor.
  23. Raf-1 Inhibitor

    GW 5074 is a potent, selective and cell-permeable c-Raf1 kinase inhibitor
  24. VEGFR1/2/3/PDGFRβ/Kit/RET/Raf-1 inhibitor

    Regorafenib Hydrochloride is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.
  25. p38 MAPK inhibitor

    SB 239063 is a potent and selective p38 MAP kinase inhibitor (IC50 = 44 nM for p38α). SB 239063 displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580. SB 239063 reduces inflammatory cytokine production and is neuroprotective following oral administration in vivo.
  26. p38 MAPK inhibitor

    SD-06 is a p38 MAP kinase inhibitor; inhibits p38α with an IC50 value of 170 nM and inhibits LPS-stimulated TNF-release in rats (83% inhibition at 1mg/kg, po).
  27. BMK1/ERK5 inhibitor

    XMD8-92 is a potent and selective BMK1/ERK5 inhibitor .
  28. nAChR agonist

    Varenicline Tartrate(CP 526555;Champix) is a nicotinic receptor partial agonist; it stimulates nicotine receptors more weakly than nicotine itself does.
  29. JNK Inhibitor IX

    TCS JNK 5a is a highly selective inhibitor of JNK2 and JNK3 (pIC50 values are 6.7, 6.5, <5.0 and <4.8 for JNK3, JNK2, JNK1 and p38&alpha; respectively).

  30. Raf kinase inhibitor

    Sorafenib N-Oxide is a metabolite of Sorafenib, a potent Raf kinase inhibitor.
  31. Asiaticoside (Madecassol) is the active chemical component of the plant Centella asiatica. Asiaticoside is used to study potential treatments for wounds and burns.
  32. trans-Zeatin is a member of the plant hormone family known as ??cytokinins??, which regulate cell division, development, and nutrient processing.
  33. MAP4K4 inhibitor

    GNE-495 is a potent and selective MAP4K4 inhibitor with an IC50 of 3.7 nM.
  34. ERK1/2 inhibitor

    GDC-0994 is a potent and selective Erk1/2 inhibitor. GDC-0994 inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways.
  35. Raf inhibitor

    L-779450 is a raf kinase inhibitor, a potential treatment for neurotraumatic diseases.
  36. p38 MAPK inhibitor

    Pamapimod is a novel p38 mitogen-activated protein kinase inhibitor.
  37. p38 MAPK inhibitor

    RWJ-67657 is a potent p38 MAPK inhibitor.
  38. p38 MAPK inhibitor

    Dilmapimod is p38 MAPK inhibitor.
  39. p38 MAPK inhibitor

    BMS-582949 Is a Dual Action p38 Kinase Inhibitor Well Suited To Avoid Resistance Mechanisms That Increase p38 Activation in Cells.
  40. JNK inhibitor

    CC-930 is kinetically competitive with ATP in the JNK-dependent phosphorylation of the protein substrate c-Jun and potent against all isoforms of JNK (Ki(JNK1) = 44 ?? 3 nM, IC50(JNK1) = 61 nM, Ki(JNK2) = 6.2 ?? 0.6 nM, IC50(JNK2) = 5 nM, IC50(JNK3) = 5 nM) and selective against MAP kinases ERK1 and p38a with IC50 of 0.48 and 3.4 μM respectively
  41. JNK inhibitor

    CEP-1347 is an inhibitor of c-jun N-terminal kinase (JNK) signaling. It rescues motor neurons undergoing apoptosis (EC50 = 20 nM).
  42. MAPKAP-K2 (MK-2) inhibitor

    MK-2 Inhibitor III (compound 16) is an orally active, selective, and ATP-competitive MAPKAP-K2 (MK-2) inhibitor with an IC50 of 0.85 nM.
  43. p38 MAPK inhibitor

    TA-02 is a p38 MAPK inhibitor with IC50 of 20 nM.
  44. p38 MAPK inhibitor

    SB-242235 is a potent and selective p38 MAP kinase inhibitor that may be an effective therapy for cytokine-mediated diseases such as autoimmune or inflammatory diseases.
  45. JNK inhibitor

    BI-78D3 is a competitive JNK (c-Jun N-terminal kinases) inhibitor (IC50 = 280 nM) that displays > 100 fold selectivity over p38α and no activity at mTOR and PI-3K. BI 78D3 inhibits JIP1(JNK interacting protein 1)-JNK binding (IC50 = 500 nM).
  46. Hypothemycin is a resorcylic acid lactone polyketide. It was found to inhibit the proliferation of mouse and human T cells stimulated with anti-CD3 mAb + PMA and of human PBMC stimulated with anti-CD3 mAb alone.
  47. ERK5 inhibitor

    BAY885 is a novel ERK5 inhibitor.
  48. Raf inhibitor

    CEP-32496 is an orally available v-raf murine sarcoma viral oncogene homolog B1 (B-raf) serine/threonine protein kinase inhibitor with potential antineoplastic activity.
  49. MNK2 inhibitor

    CGP 57380 is an inhibitor of MAP-kinase interacting kinase-1 (Mnk1, MKNK1) (IC50 = 2.2 uM).
  50. CK2/ERK8 inhibitor

    MCB has been shown to inhibit both casein kinase 2 (CK2) and extracellular-signal-regulated kinase 8 (ERK8/MAPK15) (IC50 = 0.50 uM for both CK2 and ERK8).

Items 451-500 of 817

Page
per page
Set Descending Direction